Biao Yang

Dr. Biao Yang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
WHWanting Hou
Wanting Hou
BYBiao Yang
Biao Yang
HZHong Zhu
Hong Zhu
Immunotherapy has dramatically changed prognosis for patients with malignant tumors. However, as a non-immunogenic tumor, pancreatic ductal adenocarcinoma (PDAC) has a low response to immunotherapy. Factors that contribute to the inefficiency of PDAC immunotherapy include the tumor microenvironment (TME) and its dense stroma, which acts as a barrier for drug delivery and immune cell infiltration. Recent studies have shown that nanoparticle-based therapeutic strategies have more promising applications in improving drug delivery and reversing the immunosuppressive TME for PDAC. Therefore, nanomaterial-based therapeutic approaches are expected to enhance the effectiveness of immunotherapy and improve prognosis of patients with PDAC. Here, we outline the status and dilemma of PDAC immunotherapy, and summarize the latest advances in nanoparticle-based treatment strategies to enhance the efficacy of PDAC immunotherapy.

12 May 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ZHZhe Hu
Zhe Hu
PYPengfei Yue
Pengfei Yue
MYMinlan Yuan
Minlan Yuan
ZZZhenjie Zhang
Zhenjie Zhang
QLQiaoqi Li
Qiaoqi Li
ZCZhongwei Cao
Zhongwei Cao
Background: Hepatocellular carcinoma ranks among the most prevalent malignancies worldwide. While stress can modulate tumor initiation, progression, metastasis, and therapeutic response through diverse mechanisms, its specific role in hepatocellular carcinoma pathobiology remains elusive. This study aimed to elucidate the role of the gut microbiota in stress-promoted hepatocellular carcinoma progression and to uncover the pathways associated with disease progression. Methods: Integrating clinical and preclinical models, we delineated stress-induced restructuring of the gut microbiota and functionally restored specific microbial constituents. Mechanistic insights into the microbial metabolite indole-3-propionic acid were derived through in vitro and in vivo interrogations of the hepatocellular carcinoma tumor microenvironment. Results: Stress profoundly remodels the gut microbiota, with Phocaeicola vulgatus being significantly reduced. Restoration of Phocaeicola vulgatus or administration of its tryptophan-derived metabolite indole-3-propionic acid significantly attenuated hepatocellular carcinoma progression in vivo . Indole-3-propionic acid treatment reduced endothelial JAM2 expression and was associated with reduced JAM2–F11R-mediated endothelial–macrophage crosstalk in hepatocellular carcinoma, which may contribute to suppression of tumor progression. Conclusions: These findings support a role for the stress–gut microbiota–metabolite–tumor microenvironment axis in hepatocellular carcinoma progression and suggest potential translational targets for microbiome-based therapeutic strategies.

1 July 2025 in Quantitative Imaging in Medicine and Surgery
Verified
Journal Article
Open access
PDF file
QLQiaoqi Li
Qiaoqi Li
JWJuan Wu
Juan Wu
HMHanjun Mo
Hanjun Mo
CYCheng Yi
Cheng Yi
XTXiaoqiang Tang
Xiaoqiang Tang
BYBiao Yang
Biao Yang
Transarterial chemoembolization for inoperable primary cardiac angiosarcoma: a description of two cases and literature analysis

2 July 2026 in Cell Stem Cell
Verified
Journal Article
Closed access
BDBi-Sen Ding
Bi-Sen Ding
BYBiao Yang
Biao Yang
ZCZhongwei Cao
Zhongwei Cao